Total Payments
$1.6M
2024 Payments
$133,309
Companies
49
Transactions
1,007
Medicare Patients
14,702
Medicare Billing
$5.0M
Payment Breakdown by Category
Consulting$1.0M (61.8%)
Other$308,236 (18.8%)
Travel$195,776 (12.0%)
Research$106,246 (6.5%)
Food & Beverage$14,523 (0.9%)
Education$826.77 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.0M | 352 | 61.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $270,237 | 102 | 16.5% |
| Travel and Lodging | $195,776 | 178 | 12.0% |
| Unspecified | $106,246 | 54 | 6.5% |
| Honoraria | $23,876 | 18 | 1.5% |
| Food and Beverage | $14,523 | 260 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,284 | 4 | 0.6% |
| Long term medical supply or device loan | $2,614 | 30 | 0.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $1,875 | 1 | 0.1% |
| Education | $826.77 | 7 | 0.1% |
| Grant | $350.00 | 1 | 0.0% |
Payments by Type
General
$1.5M
953 transactions
Research
$106,246
54 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $259,348 | 85 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $185,483 | 136 | $0 (2024) |
| Merck Sharp & Dohme LLC | $161,523 | 60 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $127,873 | 107 | $0 (2024) |
| F. Hoffmann-La Roche AG | $127,538 | 85 | $0 (2024) |
| AstraZeneca UK Limited | $114,632 | 48 | $0 (2024) |
| Seagen Inc. | $105,434 | 63 | $0 (2023) |
| PFIZER INC. | $98,707 | 52 | $0 (2024) |
| Eli Lilly and Company | $60,700 | 80 | $0 (2024) |
| Novartis Pharma AG | $45,261 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $133,309 | 106 | Merck Sharp & Dohme LLC ($26,858) |
| 2023 | $334,625 | 170 | Lilly USA, LLC ($76,854) |
| 2022 | $185,539 | 114 | Merck Sharp & Dohme LLC ($36,922) |
| 2021 | $238,151 | 112 | Lilly USA, LLC ($38,063) |
| 2020 | $159,557 | 100 | Novartis Pharmaceuticals Corporation ($25,416) |
| 2019 | $238,290 | 171 | Lilly USA, LLC ($52,407) |
| 2018 | $192,676 | 120 | Lilly USA, LLC ($49,766) |
| 2017 | $153,969 | 114 | AstraZeneca Pharmaceuticals LP ($25,085) |
All Payment Transactions
1,007 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,330.00 | General |
| 12/20/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,460.00 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $117.93 | General |
| Category: Oncology | ||||||
| 12/03/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $665.00 | General |
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Oncology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: BioOncology | ||||||
| 11/06/2024 | Genentech USA, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: BioOncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Travel and Lodging | In-kind items and services | $347.58 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Travel and Lodging | In-kind items and services | $315.81 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Travel and Lodging | Cash or cash equivalent | $235.78 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $95.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | Cash or cash equivalent | $27.59 | General |
| Category: Oncology | ||||||
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,990.00 | General |
| 10/17/2024 | PFIZER INC. | IBRANCE (Drug) | Honoraria | Cash or cash equivalent | $2,920.00 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Roche Products Limited | — | Consulting Fee | Cash or cash equivalent | $330.00 | General |
| 10/09/2024 | PFIZER INC. | TUKYSA (Drug) | Honoraria | Cash or cash equivalent | $2,310.00 | General |
| Category: Oncology | ||||||
| 10/04/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,662.50 | General |
| 10/03/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $25,500 | 3 |
| CLEE011O12301C | Novartis Pharmaceuticals Corporation | $11,205 | 3 |
| KISQALI Study Related Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $8,184 | 1 |
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $6,894 | 2 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $6,773 | 1 |
| PATTERNS AND PREDICTORS OF TAXANE USE FOR METASTATIC TRIPLE NEGATIVE BREAST CANCER PATIENTS IN THE U.S. | F. Hoffmann-La Roche AG | $5,332 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $5,193 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH PIQRAY RESEARCH | Novartis Pharmaceuticals Corporation | $4,375 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN COMBINATION IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER | F. Hoffmann-La Roche AG | $3,702 | 5 |
| A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER | F. Hoffmann-La Roche AG | $3,200 | 6 |
| CLEE011A2301 | Novartis Pharmaceuticals Corporation | $3,108 | 1 |
| ABI-007-MBC-001 | Celgene Corporation | $2,631 | 2 |
| GIREDESTRANT in 1L HER2 ER mBC patients | F. Hoffmann-La Roche AG | $2,466 | 1 |
| INCIDENCE OF ANAPHYLAXISHYPERSENSITIVITY FOLLOWING THE USE OF INTRAVENOUS PERTUZUMAB PLUS TRASTUZUMAB PH OR THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION PH FDC SC FOR THE TREATMENT OF HER2-POSITIVE BREAST CANCER BC A META-ANALYSIS TBC | F. Hoffmann-La Roche AG | $2,348 | 1 |
| Ipatasertib in combination with paclitaxel in TNBC and HR Breast Cancer | F. Hoffmann-La Roche AG | $2,257 | 3 |
| MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE OF PRIOR ENDOCRINE TREATMENT | Novartis Pharmaceuticals Corporation | $2,045 | 1 |
| CBYL719C2202 | Novartis Pharma AG | $1,875 | 1 |
| CLEE011O12001 | Novartis Pharma AG | $1,400 | 1 |
| Crossed over PH fixed dose co formulation FDC SC preference study | F. Hoffmann-La Roche AG | $1,332 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,238 | 2 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CAAKT1PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER | F. Hoffmann-La Roche AG | $1,182 | 1 |
| ABI-007-MBC-001 - A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly nab -Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjec | Celgene Corporation | $1,156 | 1 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CAAKT1PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER | F. Hoffmann-La Roche AG | $1,005 | 4 |
| AN OBSERVATIONAL COHORT STUDY OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2 POSITIVE HER2 METASTATIC BREAST CANCER SYSTHERS REGISTRY SYSTEMATIC THERAPIES FOR HER2 METASTATIC BREAST CANCER STUDY | F. Hoffmann-La Roche AG | $824.00 | 1 |
| IMPACT OF STEROID PREMEDICATION ON ATEZOLIZUMAB-INDUCED IMMUNE CELL ACTIVATION A COMPARATIVE ANALYSIS OF IMPASSION130 AND IMPASSION131 PERIPHERAL BLOOD MONONUCLEAR CELLS | F. Hoffmann-La Roche AG | $533.69 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR PIQRAY RESEARCH | Novartis Pharmaceuticals Corporation | $317.00 | 1 |
| Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine T-DM1 for Patients With Advanced or Metastatic HER2 Breast Cancer | Seattle Genetics, Inc. | $106.67 | 1 |
| IMPACT OF STEROID PREMEDICATION ON ATEZOLIZUMAB ATEZO-INDUCED IMMUNE CELL ACTIVATION A COMPARATIVE ANALYSIS OF IMPASSION130 AND IMPASSION131 PERIPHERAL BLOOD MONONUCLEAR CELLS PBMCS | F. Hoffmann-La Roche AG | $63.69 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 63 | 3,907 | 111,460 | $8.2M | $1.9M |
| 2022 | 66 | 3,879 | 82,380 | $5.5M | $1.3M |
| 2021 | 62 | 3,952 | 68,239 | $4.3M | $951,897 |
| 2020 | 52 | 2,964 | 49,957 | $3.5M | $853,293 |
Total Patients
14,702
Total Services
312,036
Medicare Billing
$5.0M
Procedure Codes
243
All Medicare Procedures & Services
243 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 58 | 25,900 | $3.5M | $1.1M | 31.6% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 5,040 | $641,880 | $191,554 | 29.8% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 13 | 3,240 | $735,480 | $147,458 | 20.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 28 | 6,540 | $429,960 | $120,236 | 28.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 222 | 486 | $343,602 | $50,640 | 14.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 85 | 258 | $127,968 | $34,685 | 27.1% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 22 | 30 | $144,060 | $34,435 | 23.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 14 | 240 | $323,520 | $17,745 | 5.5% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 79 | 88 | $93,896 | $16,236 | 17.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 163 | 592 | $92,944 | $13,611 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 132 | $48,576 | $12,423 | 25.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 78 | 166 | $57,104 | $8,557 | 15.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 322 | 792 | $50,688 | $8,178 | 16.1% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 11 | 830 | $202,520 | $6,795 | 3.4% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 69 | 331 | $42,368 | $6,730 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $28,360 | $6,696 | 23.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 99 | 131 | $41,003 | $6,625 | 16.2% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 105 | 118 | $96,878 | $6,567 | 6.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 312 | 777 | $15,540 | $6,511 | 41.9% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 69 | 329 | $32,571 | $6,096 | 18.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 315 | 738 | $26,568 | $5,602 | 21.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 35 | 91 | $19,201 | $5,131 | 26.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 150 | 394 | $42,552 | $4,816 | 11.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 19 | 11,220 | $56,100 | $4,481 | 8.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 16 | 29 | $14,500 | $3,916 | 27.0% |
About Dr. Joyce O'shaughnessy, MD
Dr. Joyce O'shaughnessy, MD is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790727709.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joyce O'shaughnessy, MD has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $133,309 received in 2024. These payments were reported across 1,007 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($1.0M).
As a Medicare-enrolled provider, O'shaughnessy has provided services to 14,702 Medicare beneficiaries, totaling 312,036 services with total Medicare billing of $5.0M. Data is available for 4 years (2020–2023), covering 243 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Dallas, TX
- Active Since 06/12/2006
- Last Updated 04/24/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1790727709
Products in Payments
- VERZENIO (Drug) $161,157
- KISQALI (Drug) $122,441
- IBRANCE (Drug) $81,806
- TECENTRIQ (Biological) $54,115
- TUKYSA (Drug) $50,032
- Herceptin (Biological) $46,063
- Halaven (Drug) $40,645
- LYNPARZA (Drug) $36,628
- PIQRAY (Drug) $34,737
- Orserdu (Drug) $31,082
- KEYTRUDA (Biological) $30,318
- Afinitor (Drug) $23,471
- LEE011 (Drug) $16,481
- NERLYNX (Drug) $14,570
- Nerlynx (Drug) $14,452
- Perjeta (Biological) $12,128
- Non-Covered Product (Drug) $10,735
- Abraxane (Drug) $9,936
- Zoladex (Drug) $9,217
- BYL719 (Drug) $8,450
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262
Dr. Stephen Jones, Md, MD
Medical Oncology — Payments: $221,960
Medical Oncology $221,960